Lentiviral Vector/Transgene/Biomarker RNA Biodistribution Analysis

The RNA ISH (In Situ Hybridization) technology is an excellent solution for detecting lentiviral vector DNA and therapeutic transgene mRNA expression within intact tissue morphology, addressing critical questions on tissue biodistribution, persistence, cellular tropism, and vector promoter activity. As a leading technology provider, Creative Bioarray's elite scientists have broad experience in Lentiviral Vector/transgene/Biomarker RNA Biodistribution Analysis (RNA ISH method), which can supply the best service for you.

RNA ISH assay is a powerful tool to study gene expression at the single-cell level. Its application in the study of lentiviral vector/transgene/biomarker RNA biodistribution in gene therapy has several advantages:

• Specificity: RNA FISH allows for the highly specific detection of specific transcripts in different cells and tissues, which can substantially aid in identifying the precise location where lentiviral vectors are administered and transgenes are expressed.
• Sensitivity: It allows the detection of low-abundance RNA molecules, making it extremely sensitive. This is particularly important for the detection of therapeutic genes delivered by lentiviral vectors that may be expressed at low levels.
• Spatial Information: With this technique, it is possible to maintain the spatial information related to RNA expression. Thus, it facilitates the understanding of the distribution patterns of lentiviral vectors and transgenes within a particular tissue or cell population.
• Multiplex: RNA FISH can be modified as multiplexed assays for simultaneous detection of multiple target RNAs in a single sample.
• Quantitative: RNA FISH provides quantitative data, enabling the direct comparison of gene expression levels between different cells or tissues.

As the field of gene therapy is advancing rapidly, the use of lentiviral vector uncovers further challenges and possibilities. The Lentiviral Vector/transgene/Biomarker RNA Biodistribution Analysis from Creative Bioarray can be used to evaluate the efficiency of gene therapies by quantifying the expression level of transgenes delivered by lentiviruses.

Features of Lentiviral Vector/transgene/Biomarker RNA Biodistribution Analysis (RNA ISH method)

(1) Detection of single-copy DNA vectors

(2) Codon-optimized transgene and biomarker expression analysis

(3) Custom probes designed within 1-2 weeks

(4) Fastest turnaround time

Benefits of Lentiviral Vector/transgene/Biomarker RNA Biodistribution Analysis (RNA ISH method)

(1) Simultaneously visualize in vivo delivery of vector DNA and therapeutic transgene mRNA

(2) Identify cell tropism of vector by multiplexing with cell-type markers

(3) Distinguish transgene from endogenous sequences, at the single nucleotide level

Creative Bioarray offers Lentiviral Vector/transgene/Biomarker RNA Biodistribution Analysis for you as follows:

• Probe design
• Probe synthesis
• ISH staining
• Imaging
• Data analysis

Quotation and ordering

Our customer service representatives are available 24hr a day! We thank you for considering Creative Bioarray as your Lentiviral Vector/transgene/Biomarker RNA Biodistribution Analysis partner.

References

1. Food and Drug Administration, 1991, Points to consider in human somatic cell therapy and gene therapy
2. Bosse, Roland, et al. "Good manufacturing practice production of human stem cells for somatic cell and gene therapy." Stem cells 15.S2 (1997): 275-280.
3. Pilaro, Anne M., and Mercedes A. Serabian. "Preclinical development strategies for novel gene therapeutic products." Toxicologic pathology 27.1 (1999): 4-7.
4. Verdier, F., and J. Descotes. "Preclinical safety evaluation of human gene therapy products." Toxicological sciences: an official journal of the Society of Toxicology 47.1 (1999): 9-15.
5. Podsakoff, Greg M. "Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector." Molecular Therapy 4.4 (2001): 282-283.
6. Naldini, Luigi, et al. "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector." Science 272.5259 (1996): 263-267.
7. Romano, Gaetano, et al. "Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications." Stem cells 18.1 (2000): 19-39.
8. Pan, Dao, et al. "Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow." Molecular Therapy 6.1 (2002): 19-29.
9. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ, Bueren J, Baum C. Insertional Transformation of Hematopoietic Cells by Self-inactivating Lentiviral and Gammaretroviral Vectors. Mol Ther. 2009